Introduction: The choice of therapy in patients withdrawing from natalizumab treatment is still
INTRODUCTION
Alemtuzumab was approved by the EMA in 2013 for active relapsing-remitting multiple sclerosis (RRMS) patients. It is considered an induction treatment, since it causes lymphocyte depletion followed by cellular repopulation [1] . For this reason, the ideal candidate is an active patient in an early phase of the disease. In the real world, alemtuzumab is also used as a ''third line'' therapy, when many prior treatments have failed.
At present, neurologists also have other highly active drugs [2] , but there are no head-to-head studies directly comparing the efficacy of alemtuzumab with other efficacious therapies such as natalizumab or fingolimod. Therefore, the decision to choose the most Clinical evaluation performed at 6 months and at 12 months showed stability, in particular, neither relapses nor increase in EDSS were observed.
DISCUSSION
The therapeutic landscape of multiple sclerosis (MS) is dramatically changing and becoming more and more complex for many reasons: (1) very early treatment is highly recommended [3] [4] [5] [6] [7] ; (2) the number of therapeutic options has increased and the therapeutic algorithm is not fully established [2] ; (3) very effective drugs are available; (4) tolerance toward the disease activity has been reduced, with the introduction of the criteria of no evidence of disease activity (NEDA) [8] ; (5) In this study, we used alemtuzumab after natalizumab interruption. Patients in our study share some common characteristics: a very aggressive disease course before starting natalizumab, a high risk of PML, a stable phase of the disease during the natalizumab therapy and a very high quality of life. We had to take into consideration the need to treat a very severe disease and the safety profile of the drug to which we were switching, as well as to balance the risk of using aggressive drugs with the risk of a recurrence of disease activity if using less aggressive treatments.
Alemtuzumab is a very effective drug used successfully in patients with highly aggressive disease [28, 29] and the main side effect is the risk of autoimmunity [30] . Based on these data, we decided to use alemtuzumab and to start it 2 months after the last natalizumab infusion.
It is known that PML can occur a few months after withdrawing natalizumab, and that 
